RBC Capital analyst Ben Hendrix lowered the firm’s price target on Ardent Health (ARDT) to $16 from $21 and keeps an Outperform rating on the shares after its Q3 results. Shares declined after elevated professional fees and payer denial activity caused the company to lower its 2025 adjusted EBITDA guidance, with management expecting headwinds to continue in 2026, the analyst tells investors in a research note. The persistency of the headwinds is discouraging, though the firm was pleased to see the company launch an expanded set of margin enhancement initiatives, the firm added.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health price target lowered to $17 from $19 at Loop Capital
- Ardent Health price target lowered to $13 from $21 at Truist
- Ardent Health price target lowered to $12 from $19 at Goldman Sachs
- Ardent Health price target lowered to $17 from $21 at Stephens
- Cautious Hold on Ardent Health Partners Amidst Guidance Cuts and Competitive Disadvantages